Cambridge, Mass.– AIRNA, a biotechnology firm focused on RNA editing therapeutics, has appointed Dr. Jacob Elkins as its new Chief Medical Officer, the company announced Tuesday. Elkins, a seasoned neurologist and biopharmaceutical executive, brings more than 20 years of experience in translational and clinical drug development to the role.
Dr. Elkins will lead clinical strategy and execution at AIRNA, with an initial focus on advancing AIR-001, the company’s lead RNA editing candidate for alpha-1 antitrypsin deficiency (AATD), a rare genetic disorder. The company plans to submit AIR-001 for regulatory review later this year.
“Jake’s deep experience in genetic medicine and his successful track record in clinical development will be of great value to AIRNA as we work to deliver the promise of RNA editing for patients,” said Kris Elverum, AIRNA’s President and CEO.
Before joining AIRNA, Dr. Elkins served as Head of Development Sciences and Chief Medical Officer at Sarepta Therapeutics, where he supported the development of ELEVIDYS®, the first FDA-approved gene therapy for Duchenne muscular dystrophy. He also held senior roles at Biogen, most recently as Vice President of Experimental Neurology Research and Early Development, where he led efforts in RNA therapeutic development.
“AIR-001’s differentiated chemistry offers strong RNA editing potency with minimal off-target effects, making it a promising candidate for a best-in-class treatment,” said Dr. Elkins. “I’m excited to help bring new therapeutic options to patients and further develop RNA editing as a precision medicine platform.”
Dr. Elkins earned his M.D. from Harvard Medical School and completed his neurology residency and fellowship at the University of California, San Francisco.
